JLK (CEO Dongmin Kim) announced on the 7th that it has signed a distribution contract with Creabo, a healthcare subsidiary of Japanese general trading company Marubeni Group, and is making full-scale inroads into the Japanese market.
Through this contract, JLK has secured an official distribution network that can directly supply products to Japanese medical institutions, focusing on AI-based CT analysis solutions (JLK-CTP, NCCT, etc.) and brain imaging quantification technology (PWI, etc.). Based on this, actual sales generation is expected in a short period of time.
The Marubeni Group is one of Japan’s top five general trading companies, and is building a global network in various fields such as energy, food, industrial materials, and healthcare. Among them, Creabo is focusing on utilizing Marubeni’s global network to discover AI-based medical devices and obtain business licenses and commercialize services to provide products to medical institutions in Japan.
As a local specialized partner with a deep understanding of the purchasing and decision-making processes of Japanese medical institutions, Creabo is expected to play a key role in generating stable and recurring sales of JLK products.
The medical AI industry is evaluating this contract as a turning point that goes beyond simple exports and secures sales channels in Japan and increases corporate value. In particular, the collaboration with Creabo, which has extensive distribution experience in Japan, is expected to lower the barriers to introducing AI solutions.
In addition, this contract is expected to serve as a bridgehead for not only short-term sales but also expansion of distribution channels in Japan, securing references from public hospitals, and expanding cooperation with global pharmaceutical and IT companies.
JLK CEO Kim Dong-min said, “Through this contract, we expect great results in the Japanese market, which is rapidly aging,” and “We will make 2025 the first year of full-scale entry into the Japanese market and accelerate global expansion and enhancing corporate value.”
- See more related articles
You must be logged in to post a comment.